{"id":239020,"date":"2026-06-15T22:06:19","date_gmt":"2026-06-16T03:06:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/06\/reliable-detection-of-sglt2-protein-by-knockout-based-antibody-characterization"},"modified":"2026-06-15T22:06:19","modified_gmt":"2026-06-16T03:06:19","slug":"reliable-detection-of-sglt2-protein-by-knockout-based-antibody-characterization","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/06\/reliable-detection-of-sglt2-protein-by-knockout-based-antibody-characterization","title":{"rendered":"Reliable Detection of SGLT2 Protein by Knockout-Based Antibody Characterization"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/reliable-detection-of-sglt2-protein-by-knockout-based-antibody-characterization2.jpg\"><\/a><\/p>\n<p>BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) mediates renal glucose reabsorption, and its pharmacological inhibition exerts cardio-and renoprotective benefits. Despite widespread clinical interest, reliable detection of SGLT2 protein remains challenging due to concerns regarding antibody specificity. METHODS: Eight commercially available anti-SGLT2 antibodies were evaluated by immunohistochemistry and Western blotting using kidneys and hearts from genetically engineered Sglt2-deficient mice and rats. Human kidney tissues, including renal cell carcinoma samples, were also examined. RESULTS: Among the antibodies tested, ab306558 and HPA041603 showed specific immunostaining in rodent kidneys, with minimal background in wild-type tissues and complete absence of staining in Sglt2-deficient samples. However, ab306558 was unsuitable for human samples because of nonspecific staining.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) mediates renal glucose reabsorption, and its pharmacological inhibition exerts cardio-and renoprotective benefits. Despite widespread clinical interest, reliable detection of SGLT2 protein remains challenging due to concerns regarding antibody specificity. METHODS: Eight commercially available anti-SGLT2 antibodies were evaluated by immunohistochemistry and Western blotting using kidneys and hearts from genetically engineered Sglt2-deficient [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,19,412],"tags":[],"class_list":["post-239020","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-chemistry","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=239020"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239020\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=239020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=239020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=239020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}